Humana (HUM) Financials

Humana’s latest quarter shows a clear rebound in profitability and cash generation after a very weak close to 2025. For Q1 2026, the company posted net income of $1.18 billion versus a $776 million loss in Q4 2025, while operating cash flow improved to $1.25 billion from negative $1.65 billion in the prior quarter. That is a meaningful turnaround for a healthcare insurer that had been under pressure.

Revenue also improved sequentially. Total revenue reached $39.6 billion in Q1 2026, up from $32.5 billion in Q4 2025. More importantly, operating income swung back to $1.75 billion from a $808 million operating loss, suggesting Humana is recovering from the margin compression seen late last year.

• Operating income recovered sharply to $1.75 billion in Q1 2026 from a $808 million loss in Q4 2025.
• Operating cash flow rebounded to $1.25 billion, indicating better underlying cash generation.
• The balance sheet remains liquid, with $4.95 billion in cash and $17.0 billion in short-term investments.
• Total current assets of $38.1 billion comfortably exceed current liabilities of $21.5 billion.
• Net income of $1.18 billion marks a major improvement from the prior quarter’s loss.
• Equity improved to $18.6 billion, up from $16.4 billion at year-end 2024.
• Weighted average shares were essentially unchanged at 120.1 million, so EPS gains were driven by better earnings rather than share count changes.
• The company still carries a large amount of goodwill, at $10.5 billion, which is worth watching in a slower-growth or acquisition-heavy environment.
• Long-term debt remains elevated at $12.3 billion, and total liabilities of $36.6 billion are still substantial.
• Humana is not yet back to its 2024 operating levels; in Q1 2024, operating income was $2.0 billion, above the latest quarter’s $1.75 billion.

Looking at the broader trend over the last four years, Humana’s results have been volatile but still resilient. The company generated strong profitability through much of 2023 and early 2024, then saw a sharp deterioration in late 2024 and Q4 2025. The recent quarter suggests that downturn may have been temporary, but investors should still be cautious: the business is healthy enough to produce strong cash, yet not so stable that execution risk can be ignored.

One encouraging sign is that Humana has continued to generate enough cash to support dividends, investments, and debt repayment. In Q1 2026 it paid $107 million in dividends and repaid $665 million of debt, even after funding acquisitions and investment purchases. That points to a company with financial flexibility.

The main takeaway for retail investors is that Humana appears to be recovering from a rough patch. The latest quarter was materially better across earnings, operating income, and cash flow, and the balance sheet remains solid. The key question now is whether management can sustain this improvement and avoid another margin setback in the quarters ahead.